Kancera has received approval to start the final part of the phase Ib program for KAND567


Kancera AB (Nasdaq First North Premier Growth Market: KAN) today announces that it has received approval from the Finnish Medicines Agency Fimea and the Ethics Committee to start the final part of the phase Ib program for KAND567. The company estimates that the results of the study may become available in March 2020. The timetable is thus unchanged for the completion of the fully guaranteed issue during the current quarter.

The drug candidate KAND567 is being developed to protect the heart and blood vessels from damage in connection with acute heart attack. Kancera plans to initiate a phase IIa study later this year in which KAND567 will be administered in the form of an initial intravenous infusion followed by oral treatment. Oral administration of the drug candidate has shown good safety and tolerability in earlier phase I studies.

In the final part of the Phase Ib program, infusion of KAND567 will be given at a higher concentration but for a shorter time than in the previous part of the program. This is to minimize the risk of transient local irritation at the infusion site that has been previously observed. The purpose of the study is to document the safety and tolerability of the treatment in healthy subjects.

It is gratifying that we can now continue with the concluding part of the phase Ib program, which aims to pave the way for the first study of KAND567 in patients. The rapid approval from the Finnish Medicines Agency means that we still expect to apply for a phase IIa study in the second quarter of 2020, says Thomas Olin, CEO of Kancera.

About Kancera

Kancera develops drugs that counteract damage during acute and chronic inflammation. The Fractalkine blocker KAND567 is primarily developed to effectively and selectively reduce the inflammation of the heart and vessels following a heart attack and is expected to enter the clinical phase II study during the first half of 2020. Since scientific studies have shown elevated levels of fractalkine not only in heart attacks but also in inflammatory diseases and certain forms of cancer, there are several possible development opportunities for the fractalkine blockers KAND567 and KAND145. Kancera also develops preclinical drug projects against cancer aimed at stopping survival signals in the cancer cell and preventing the cancer cell’s ability to be repaired. Kancera operates at Karolinska Institutet Science Park in Stockholm. The share is traded on Nasdaq First North. FNCA Sweden AB (tel. 08-528 00 399, info@fnca.se) is the company’s Certified Adviser. MD PhD Charlotte Edenius, MD PhD Anders Gabrielsen, Professor Carl-Henrik Heldin and Professor Håkan Mellstedt are all scientific advisors and board members of Kancera AB.

For further information, contact:
Thomas Olin, CEO: +46-(0)735-20 40 01

Kancera AB (publ)
Karolinska Institutet Science Park
Banvaktsvägen 22
SE 171 48 Solna

We welcome you to visit our home-page: www.kancera.com